Global Blood Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ted Love
- Full Time Employees
- 457
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 181 OYSTER POINT BLVD South San Francisco CA United States of America 94080
- IPO Date
- Aug 12, 2015
- CIK
- 0001629137
- Website
- gbt.com
- Similar Companies
- Business
- Global Blood Therapeutics, Inc. Global Blood Therapeutics, Inc. (GBT), founded in 2011 and headquartered in South San Francisco, California, is a biopharmaceutical company focused on the discovery, development, and commercialization of therapies for sickle cell disease (SCD) and other blood disorders; its primary product is Oxbryta (voxelotor), an oral, once-daily therapy approved by the FDA for treating SCD in patients aged four years and older by increasing hemoglobin's affinity for oxygen to inhibit sickle hemoglobin polymerization, hemolysis, and hemolytic anemia; the company previously advanced a pipeline including inclacumab, a P-selectin inhibitor for reducing vaso-occlusive crises in SCD, and GBT601 (osivelotor), an oral HbS polymerization inhibitor. GBT operates primarily in the United States with approvals and marketing authorizations extending to Europe, Great Britain, and Gulf Cooperation Council countries including Kuwait, Oman, and the United Arab Emirates, targeting underserved patient communities affected by SCD, a lifelong inherited blood disorder prevalent in populations of African, Middle Eastern, and South Asian descent. In October 2022, Pfizer Inc. completed its $5.4 billion acquisition of GBT, making it a wholly owned subsidiary and integrating its portfolio and pipeline into Pfizer's rare hematology efforts; subsequently, Pfizer withdrew Oxbryta from global markets in 2024 after post-approval data indicated its benefits no longer outweighed risks, and in August 2025, Pfizer's phase 3 THRIVE study of inclacumab missed its primary endpoint of reducing vaso-occlusive crises, though the company continues development of osivelotor in phase 3 and reaffirms commitment to SCD innovation.
BMTC Group (TSE:GBT) Stock Price Crosses Below 50-Day Moving Average – What’s Next?
Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals
GLOBAL BLOOD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Global Blood Therapeutics, Inc. - GBT
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates AAWW, GBT, CYBE, AVLR
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GBT, AVLR, CYBE, SBCF
Get ready for more merger mania in pharma sector the rest of the year
Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings
Pfizer is acquiring Global Blood Therapeutics
Pfizer to buy Global Blood Therapeutics for US$5.4bn
SHAREHOLDER ALERT: Weiss Law Investigates Global Blood Therapeutics, Inc.
Why Global Blood Therapeutics Stock Was Trouncing the Market Today
GBT Stock Alert: Pfizer Is Officially Acquiring Global Blood Therapeutics
Pfizer Inks $5.4 Billion Deal To Acquire Global Blood Therapeutics
Pfizer Buys Global Blood Therapeutics. How the Deal Could Solve Pipeline Worries.
Why Pfizer (PFE) Is Buying Global Blood Therapeutics (GBT) For $5.4 Billion
Pfizer reaches $5.4B deal for Global Blood Therapeutics
Pfizer confirms to acquire Global Blood Therapeutics for $5.4 billion in deal that gives it access to sickle-cell disease treatment
Pfizer to buy Global Blood Therapeutics in $5.4 billion deal
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
Pfizer agrees to buy Global Blood Therapeutics in deal valued at $5.4 billion: WSJ